Antitumor properties of influenza virus vectors

Area of Science:

• Oncolytic virology
• Immunotherapy
• Viral vector technology

Background:

• Influenza virus vectors expressing tumor-associated antigens (TAAs) are being explored for cancer treatment.
• Previous studies demonstrated regression of pulmonary metastases using these vectors via cytotoxic T-cell responses.

Purpose of the Study:

• To evaluate the efficacy of recombinant influenza viruses expressing TAAs as therapeutic agents in a mouse model, using survival as the primary endpoint.
• To investigate the mechanisms of tumor response and resistance to this novel cancer therapy.

Main Methods:

• Recombinant influenza viruses engineered to express specific TAAs were administered to mice with varying tumor burdens.
• Survival rates, tumor regression, TAA expression levels, and TAA-specific mRNA were analyzed.
• Post-treatment tumor challenge was performed to assess long-term protection.

Main Results:

• Mice with high tumor burden showed extended survival but ultimately succumbed to large tumors with down-regulated TAA expression.
• Mice with a fivefold lower tumor burden exhibited complete tumor regression and survival beyond six months.
• Treated mice demonstrated protection against subsequent tumor challenge six months post-therapy.

Conclusions:

• Recombinant influenza viruses expressing TAAs can induce significant tumor regression and long-term survival in a mouse model.
• This approach holds potential for the prevention and treatment of cancers expressing known TAAs.
• Further research is warranted to optimize TAA expression and delivery for enhanced therapeutic outcomes.